Researchers conducted a large analysis of breast cancer cell function, saying the results suggest dozens of new uses for existing drugs, new drug discovery targets, and new drug combinations.
Array BioPharma reported top-line results from the ongoing phase III clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, demonstrating that the study met its primary endpoint of improving progression-free survival when compared with dacarbazine treatment.
A phase III study of the Delcath Hepatic Delivery System (Melphalan/HDS) for the treatment of melanoma patients with liver metastases, met its primary endpoint of hepatic progression-free survival.
A phase III study of Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, demonstrated improvements in median overall survival in post-gemcitabine metastatic pancreatic cancer patients.
FDA approved Opdivo (nivolumab) injection for the treatment of patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.
Adult patients under 60 years of age with newly-diagnosed FLT3-mutated acute myeloid leukemia who received the investigational compound PKC412 (midostaurin), plus standard induction and consolidation chemotherapy, experienced a 23 percent improvement in overall survival (HR=0.77, p=0.0074), compared to those treated with standard induction and consolidation chemotherapy alone.
Results from the phase III head-to-head ENDEAVOR study comparing Kyprolis to Velcade in patients with relapsed multiple myeloma showed that patients treated with Kyprolis achieved progression-free survival of 18.7 months compared to 9.4 months (HR=0.53; 95% CI: 0.44, 0.65; p<0.0001).
FDA has requested additional clinical data from Clovis Oncology Inc., for the agency's efficacy analysis of the 500mg and 625mg BID dose patient groups for rociletinib. Clovis said it would provide the information in a major amendment to the FDA.
Researchers from The Cancer Genome Atlas Network recently published two studies—one identifying seven distinct molecular subtypes of prostate cancer, and one exploring the genetic drivers of papillary renal cell carcinoma.
According to investigators at St. Jude Children's Research Hospital, comprehensive genomic screening may be warranted for all pediatric cancer patients, not just those with a family history of cancer, based on a detailed analysis of the role of germline mutations in genes associated with cancer predisposition.
